Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Recommendations for Radiation Treatment in Pediatric Patients With Metastatic Rhabdomyosarcoma: Expert Consensus From the International Soft Tissue SaRcoma ConsorTium (INSTRuCT).

Practical radiation oncology·2026
Same author

Bone Cancers in the Philippines: Outcomes, Challenges, and Improvements.

JCO global oncology·2026
Same author

Soft tissue reporting and data system (soft tissue-RADS): framework for radiologists specializing in imaging of musculoskeletal tumors and tumor-like lesions.

Skeletal radiology·2026
Same author

Core Decompression for Osteonecrosis of the Femoral Head in Pediatric Hematologic Malignancy Survivors: A Systematic Review.

Journal of surgical orthopaedic advances·2026
Same author

Does This Imaging Make Me Look NFATC2 ? The Value of Radiologic-pathologic Correlation in NFATC2 -rearranged Sarcomas of Bone.

The American journal of surgical pathology·2026

Related Experiment Video

Updated: Jun 18, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Pediatric osteogenic sarcoma.

Han Jo Kim1, Peter N Chalmers, Carol D Morris

  • 1Hospital for Special Surgery, New York, NY, USA. kimh@hss.edu

Current Opinion in Pediatrics
|November 17, 2009
PubMed
Summary
This summary is machine-generated.

Osteosarcoma, a rare bone cancer in adolescents, now has over 60% 5-year survival rates due to advanced chemotherapy and limb-sparing surgery. Early diagnosis and a multidisciplinary team are crucial for pediatric osteosarcoma treatment.

More Related Videos

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues
02:35

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on: March 22, 2024

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Experiment Videos

Last Updated: Jun 18, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues
02:35

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published on: March 22, 2024

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Area of Science:

  • Pediatric Oncology
  • Orthopedic Oncology
  • Bone Malignancies

Background:

  • Osteosarcoma is the most common primary bone cancer in adolescents.
  • It is characterized by spindle cells producing osteoid.
  • While rare overall, it's a significant malignancy in pediatric patients.

Purpose of the Study:

  • To provide an overview of osteosarcoma presentation in pediatric patients.
  • To discuss radiographic evaluation and treatment strategies.
  • To emphasize the importance of a multidisciplinary team for prompt diagnosis and care.

Main Methods:

  • Review of current literature on osteosarcoma in pediatric populations.
  • Analysis of recent survival data and treatment outcomes.
  • Focus on advancements in chemotherapy and surgical techniques.

Main Results:

  • Current 5-year survival rates for osteosarcoma exceed 60%.
  • Limb-sparing surgery is increasingly used, though functional outcomes are debated.
  • Tertiary referral centers report improved long-term survival with modern regimens.

Conclusions:

  • Chemotherapeutic advancements have significantly improved osteosarcoma survival rates.
  • Limb-sparing surgery is a viable alternative to amputation.
  • Comprehensive care involving pediatric oncologists and orthopedic surgeons is key.